Intrahepatic Cholangiocarcinoma (Icc) Clinical Trials

13 recruiting

Intrahepatic Cholangiocarcinoma (Icc) Trials at a Glance

13 actively recruiting trials for intrahepatic cholangiocarcinoma (icc) are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in Shanghai, Boston, and Chengdu. Lead sponsors running intrahepatic cholangiocarcinoma (icc) studies include Tianjin Medical University Cancer Institute and Hospital, Erasmus Medical Center, and Cogent Biosciences, Inc..

Browse intrahepatic cholangiocarcinoma (icc) trials by phase

Treatments under study

About Intrahepatic Cholangiocarcinoma (Icc) Clinical Trials

Looking for clinical trials for Intrahepatic Cholangiocarcinoma (Icc)? There are currently 13 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Intrahepatic Cholangiocarcinoma (Icc) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Intrahepatic Cholangiocarcinoma (Icc) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Phase 2

Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)

Intrahepatic Cholangiocarcinoma (Icc)HAICDurvalumab
West China Hospital25 enrolled1 locationNCT06859684
Recruiting
Phase 2

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Colorectal NeoplasmsIntrahepatic Cholangiocarcinoma (Icc)Metastatic Colorectal Cancer (Mcrc)+1 more
National Cancer Institute (NCI)70 enrolled1 locationNCT05286814
Recruiting

Prospective Evaluation of 68Ga-FAPI PET in Biliary Cancers

Gall Bladder CancerIntrahepatic Cholangiocarcinoma (Icc)
Tata Memorial Centre60 enrolled1 locationNCT07337850
Recruiting
Not Applicable

Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN

Neuroendocrine TumorsHepatocellular Carcinoma (HCC)Intrahepatic Cholangiocarcinoma (Icc)
Nantes University Hospital60 enrolled2 locationsNCT06735560
Recruiting
Phase 2

A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC

Intrahepatic Cholangiocarcinoma (Icc)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University38 enrolled1 locationNCT06925516
Recruiting

A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening

ctDNAGall Bladder CancerIntrahepatic Cholangiocarcinoma (Icc)+3 more
Yingbin Liu, MD, PhD, FACS1,800 enrolled1 locationNCT07176962
Recruiting
Phase 2

Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma (Icc)
Fudan University56 enrolled1 locationNCT07070700
Recruiting
Phase 1Phase 2

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

CholangiocarcinomaAdvanced Solid TumorsIntrahepatic Cholangiocarcinoma (Icc)+9 more
Cogent Biosciences, Inc.110 enrolled15 locationsNCT06777316
Recruiting
Phase 2

A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma (Icc)Adjuvant ChemoradiotherapyNarrow Margin+1 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences66 enrolled1 locationNCT07063888
Recruiting
Phase 2

Additional Chemotherapy Administered Directly Into the Liver Using a Chemo Pump in Patients With Bile Duct Cancer Inside the Liver Treatable by Surgery

Intrahepatic Cholangiocarcinoma (Icc)Intrahepatic Bile Duct CancerIntrahepatic Bile Duct Carcinoma+1 more
Erasmus Medical Center40 enrolled1 locationNCT06888063
Recruiting

Liver Transplantation for Unresectable Intrahepatic Colangiocarcinoma After Sustained Response to Neoadjuvant Treatments

Intrahepatic Cholangiocarcinoma (Icc)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano14 enrolled1 locationNCT06862934
Recruiting
Phase 2

Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

Gall Bladder CancerIntrahepatic Cholangiocarcinoma (Icc)
Tianjin Medical University Cancer Institute and Hospital33 enrolled1 locationNCT06852287
Recruiting
Phase 2

Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma (Icc)
Tianjin Medical University Cancer Institute and Hospital70 enrolled1 locationNCT06721286